Component
Cyclosporin-sensitive mitochondrial matrix peptidyl-prolyl isomerase, 1990 titration
The matrix isomerase identified in rat liver and heart by binding-site number and Ki. Deliberately kept separate from PPIF: the gene assignment postdates this measurement and no claim here asserts the identity.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Liver and heart mitochondrial matrix fractions, prepared free of membrane and cytosolic contamination, contain cyclosporin-sensitive peptidyl-prolyl cis-trans isomerase, titrated at 110.6 plus or minus 10.1 and 165.4 plus or minus 15.0 picomoles of enzyme per milligram of protein with a Ki of about 2.5 nanomolar.
Experimental context and source evidence
- duration
- Not stated here
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- experimental_model
- Rat liver and heart mitochondria
- exposure
- Cyclosporin A titration
- limitations
- This is a different cyclophilin from the cytosolic one that carries the immunosuppressive mechanism, and the two must not be merged. The 1990 report identifies a matrix isomerase by activity and binding site number; the gene assignment to Ppif came later and is not part of this measurement.
- organism
- Rat liver and heart mitochondria
- plain_language
- Liver and heart mitochondrial matrix fractions, prepared free of membrane and cytosolic contamination, contain cyclosporin-sensitive peptidyl-prolyl cis-trans isomerase, titrated at 110.6 plus or minus 10.1 and 165.4 plus or minus 15.0 picomoles of enzyme per milligram of protein with a Ki of about 2.5 nanomolar.
- primary_references
- Inhibition of Ca2+-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. (1990). https://pubmed.ncbi.nlm.nih.gov/2160810/ DOI: 10.1042/bj2680153
- route
- In vitro
- tissue
- Mitochondrial matrix peptidyl-prolyl isomerase
Cyclosporine: the complex that inhibits calcineurin, a second cyclophilin, and the transport step that decides exposure (2026-09-23) · lines 124–124
Original AI-assisted curation of seven primary studies resolved by PubMed title search, with every abstract read and all DOIs cross-checked against live PubMed metadata on 2026-09-23. No reference carries a recorded retraction, erratum or expression of concern. Each of the seven is a separate laboratory and each carries its own lineage key, so none of them can be counted twice as independent support. Study-specific concentrations, kinetic constants and limitations retained. Not publisher full text. · supports · Rat liver and heart mitochondria · source_derived_draft · unverified_draft
Liver and heart mitochondrial matrix fractions, prepared free of membrane and cytosolic contamination, contain cyclosporin-sensitive peptidyl-prolyl cis-trans isomerase, titrated at 110.6 plus or minus 10.1 and 165.4 plus or minus 15.0 picomoles of enzyme per milligram of protein with a Ki of about 2.5 nanomolar.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.